• RepSox in Stem Cell Platelet Differentiation: Mechanisms & P

  2026-04-23

  Explore how RepSox, a potent ALK5 inhibitor, enables advanced induced pluripotent stem cell (iPSC) platelet production. This article uniquely deciphers practical protocols and mechanistic insights for cost-effective, high-yield differentiation.

• RBMS1 Loss Enables PD-L1 Blockade in Triple-Negative Breast

  2026-04-23

  This study identifies RBMS1 as a critical regulator of PD-L1 stability and immunosuppression in triple-negative breast cancer (TNBC). By elucidating the molecular mechanism connecting RBMS1, B4GALT1-mediated glycosylation, and PD-L1 degradation, the research offers a novel combinatorial approach to enhance anti-tumor immunity and improve immunotherapy outcomes in TNBC.

• USP42 Drives Breast Cancer Progression by Suppressing JNK/p3

  2026-04-22

  This study identifies USP42 as a key promoter of breast cancer progression through inhibition of JNK/p38-mediated apoptosis. By dissecting molecular mechanisms and employing robust in vitro and in vivo models, the work highlights USP42 as a potential therapeutic target and advances understanding of deubiquitinating enzymes in breast cancer.

• EZH1/EZH2 Inhibition Boosts Adoptive T Cell Immunotherapy Ef

  2026-04-22

  Porazzi et al. demonstrate that pharmacological inhibition of EZH1 and EZH2 can reprogram tumor cells to a more immunogenic state, thereby enhancing the efficacy of CAR-T and TCR-T cell therapies in both liquid and solid cancer models. This work provides a mechanistic and preclinical foundation for integrating dual EZH1/2 inhibition strategies, such as Valemetostat, into next-generation epigenetic cancer therapy and adoptive cell immunotherapy protocols.

• 40-Hz Light Flicker Enhances Retinal Amyloid Clearance via M

  2026-04-21

  This study demonstrates that 40-Hz light flicker boosts retinal microglial activation and MHC-II expression, leading to enhanced clearance of amyloid-β deposits in aged mice. The findings highlight a non-invasive strategy for addressing metabolic waste in retinal aging, and underscore the importance of microglial modulation—validated using minocycline hydrochloride inhibition—in age-related retinal disease models.

• SGI-1027: Innovative DNA Methyltransferase Inhibition in Can

  2026-04-21

  Explore how SGI-1027, a potent DNA methyltransferase inhibitor, is reshaping cancer epigenetics through novel mechanisms and synergy with targeted therapies. This article delves into advanced research applications and unique cytotoxic properties, setting it apart from prior content.

• Synergistic Antibacterial Action of Copper and Hexetidine In

  2026-04-20

  This study demonstrates a marked synergistic antibacterial effect when copper and hexetidine are combined against Streptococcus sobrinus and Streptococcus sanguis. The findings provide quantitative evidence for optimizing antibacterial strategies in oral microbiology, with implications for designing more effective antimicrobial protocols.

• Cefotaxime as a Research Tool: Decoding Resistance Dynamics

  2026-04-20

  Explore how Cefotaxime, a third-generation cephalosporin antibiotic, provides unique insights into antimicrobial resistance and bacterial infection modeling. This article delivers a deeper analysis of transmission dynamics and assay design for advanced research applications.

• Strategic BACE1 Inhibition: LY2886721 and the Next Era of Al

  2026-04-19

  This article provides a thought-leadership perspective for translational neuroscience, blending mechanistic insight on BACE1 inhibition with actionable guidance. It explores the biological rationale for targeting amyloid precursor protein processing, presents key experimental data on LY2886721, addresses competitive and translational landscapes, and distills lessons from recent synaptic safety evidence. The piece also outlines protocol parameters and offers a forward-looking synthesis for researchers aiming to optimize amyloid beta reduction while preserving neurophysiological integrity.

• Optimizing Workflows with Protease Inhibitor Cocktail EDTA-F

  2026-04-18

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO stands out for safeguarding protein integrity during extraction, even in divalent cation-sensitive assays. Its robust, broad-spectrum inhibition and EDTA-free formula make it indispensable for phosphorylation studies, co-immunoprecipitation, and advanced proteomic workflows.

• Carbapenemase Genes in CREC: Prevalence and Transmission in

  2026-04-17

  This study provides a comprehensive analysis of carbapenemase-encoding gene (CEG) prevalence and transmission dynamics in carbapenem-resistant Enterobacter cloacae (CREC) collected from eight teaching hospitals in Guangdong, China, during the COVID-19 pandemic. The findings reveal high rates of plasmid-mediated multidrug resistance and underscore the rapid horizontal gene transfer capacity of these genes, informing both clinical surveillance and experimental infection model design.

• GLI2 Orchestrates Tumor Immune Evasion via WNT and Prostagla

  2026-04-16

  This study identifies GLI2 as a central regulator of tumor immune evasion and resistance to immunotherapy through its coordination of WNT ligand production and prostaglandin synthesis. The findings highlight GLI2's role in shaping an immunosuppressive microenvironment and suggest new avenues for overcoming immune checkpoint blockade resistance.

• Catalpol Modulates SIRT1/HIF-1α to Counter Triptolide Liver

  2026-04-15

  This study demonstrates that Catalpol ameliorates triptolide-induced hepatic injury by activating the SIRT1/HIF-1α axis, restoring glucose metabolism and reducing oxidative stress. These mechanistic insights provide a novel therapeutic avenue for managing drug-induced liver damage and inform future translational research.

• RSL3 Glutathione Peroxidase 4 Inhibitor: Precision Ferroptos

  2026-04-14

  The (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor empowers researchers to induce ferroptosis with specificity, enabling breakthrough studies in cancer biology and redox control. Its robust selectivity for GPX4 and proven efficacy in RAS-driven tumor models make it a gold standard for dissecting iron-dependent cell death and overcoming therapy resistance.

• Ziprasidone Hydrochloride: GOT1 Inhibition and Antitumor Pat

  2026-04-13

  Explore the unique antitumor mechanisms of Ziprasidone Hydrochloride, a second-generation antipsychotic with GOT1 inhibitory activity. Delve into its dual roles in dopaminergic signaling research and cancer metabolism, and learn how APExBIO’s high-purity product enables translational breakthroughs.

443 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page